NewAmsterdam Pharma reports $728.9M cash, obicetrapib regulatory decisions expected 2H26

NewAmsterdam Pharma Co N.V.

Regulatory decisions from EMA, UK, Switzerland for obicetrapib monotherapy & FDC expected in 2H26.
Cash position $728.9M at Dec 31, 2025; net loss $203.8M for FY2025.
Topline data from RUBENS Phase 3 trial (type 2 diabetes/metabolic syndrome) expected by year-end 2026.
PREVAIL CVOT blinded event rate through initial 12 months tracking in line with BROADWAY.
Plan to initiate Alzheimer's disease trial in 2026 based on positive biomarker data from BROADWAY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.